{
    "nctId": "NCT06495164",
    "briefTitle": "A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer",
    "officialTitle": "Palbociclib Treatment Patterns and Outcomes in HR+/HER2- MBC: Flatiron Database Analysis",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Malignant Neoplasm of Breast",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 5087,
    "primaryOutcomeMeasure": "Overall Survival (OS)",
    "eligibilityCriteria": "Patients are eligible for the study if they were 18 years of age or older at MBC diagnosis, had HR+/HER2- confirmed and initiated first line therapy (CDK4/6i, ET, CT, or other) in the metastatic setting during the period from February 2015 through June 2022 or data cutoff.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}